AKTS
Aktis Oncology, Inc.Healthcare·Biotechnology
$20.74
$1.1B market cap
Revenue
$5.1M
Free Cash Flow
$-45.5M
Rev Growth
+0.0%
FCF Margin
-892.5%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a rad
2-Year Price History
$20.34-9.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 3.2 | -22.1 | -22.7 | -18.3 | -24.2 | -26.1 | -1.9 | 538.5 | 11.6 | 55.3 | -13.7% | -- | -- |
| Act | 2025-Q4 | 1.9 | -16.7 | -17.4 | -15.1 | -15.2 | -19.4 | -4.2 | 226.8 | 11.6 | 53.4 | -601.8% | -- | -- |
Valuation & Metrics
Market Stats
Price$20.74
Market Cap$1.1B
Enterprise Value$581M
P/S Ratio217.3x
P/FCF--
EV/FCF--
FCF Margin (TTM)-892.5%
FCF Yield-4.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$5.1M
Net Income$-33.5M
Free Cash Flow$-45.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin-759.9%
Net Margin-656.5%
FCF Margin-892.5%
CapEx % of Revenue117.9%
SBC % of Revenue21.5%
ROIC-307.8%
WC Change % Rev-53.2%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.6M
Days to Cover10.0
Change (vs Prior)+9.8%
Need at least 2 settlement dates for chart
Employees
Headcount79
Revenue / Employee$64,519
Gross Profit / Employee$56,266
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
53.3%
60 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
7.5%
8 filers
Vanguard, iShares, SPDR
Market makers
0.0%
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
Not enough quarterly ownership history to chart yet.
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| MPM BioImpact LLC | $86.5M | $17.89 | +$86.5M | +$86.5M | — | $1.29B |
| EcoR1 Capital, LLC | $86.3M | $17.89 | +$86.3M | +$86.3M | — | $2.34B |
| Blue Owl Capital Holdings LP | $56.6M | $17.89 | +$56.6M | +$56.6M | — | $372M |
| WELLINGTON MANAGEMENT GROUP LLP | $41.5M | $17.89 | +$41.5M | +$41.5M | — | $533.98B |
| T. Rowe Price Investment Management, Inc. | $38.0M | $17.89 | +$38.0M | +$38.0M | — | $145.22B |
| BlackRock, Inc.Passive | $37.8M | $17.89 | +$37.8M | +$37.8M | — | $5.69T |
| RTW INVESTMENTS, LP | $28.5M | $17.89 | +$28.5M | +$28.5M | — | $9.26B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $28.0M | $17.89 | +$28.0M | +$28.0M | — | $864.93B |
| RA CAPITAL MANAGEMENT, L.P. | $26.9M | $17.89 | +$26.9M | +$26.9M | — | $9.44B |
| JANUS HENDERSON GROUP PLC | $26.0M | $17.89 | +$26.0M | +$26.0M | — | $209.29B |
| BAKER BROS. ADVISORS LP | $17.8M | $17.89 | +$17.8M | +$17.8M | — | $16.13B |
| Octagon Capital Advisors LP | $17.2M | $17.89 | +$17.2M | +$17.2M | — | $904M |
| Merck & Co., Inc. | $17.0M | $17.89 | +$17.0M | +$17.0M | — | $349M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $14.9M | $17.89 | +$14.9M | +$14.9M | — | $4.04T |
| EVENTIDE ASSET MANAGEMENT, LLC | $9.1M | $17.89 | +$9.1M | +$9.1M | — | $5.96B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $8.8M | $17.89 | +$8.8M | +$8.8M | — | $1.61T |
| Avidity Partners Management LP | $8.4M | $17.89 | +$8.4M | +$8.4M | — | $505M |
| STATE STREET CORPPassive | $7.7M | $17.89 | +$7.7M | +$7.7M | — | $2.89T |
| a16z Capital Management, L.L.C. | $7.4M | $17.89 | +$7.4M | +$7.4M | — | $1.29B |
| FMR LLC | $6.9M | $17.89 | +$6.9M | +$6.9M | — | $1.89T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.81%
avg per quarter
Holders (ex-self)
—
excl. this stock
Buyers (this Q)
-1.81%
69 buyers · $0.62B in
Sellers (this Q)
+0.00%
0 sellers · $0.00B out
alpha coverage: 97% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-2.2%
how holders react when this stock falls
On quiet Qs
-3.1%
−10% to +10% baseline
On rallies (+10%+)
-3.8%
how they react when this stock rises
Holders' portfolio flow this Q
-1.6%
outflows — trims may be forced
Sellers' portfolio flow this Q
+0.0%
Sellers' overall flow ~ flat.
New buyers this quarter
MPM BioImpact LLC+$0.09BEcoR1 Capital, LLC+$0.09BBlue Owl Capital Holdings LP+$0.06BWELLINGTON MANAGEMENT GROUP LLP+$0.04BT. Rowe Price Investment Management, Inc.+$0.04BBlackRock, Inc.+$0.04BRTW INVESTMENTS, LP+$0.03BPRICE T ROWE ASSOCIATES INC /MD/+$0.03BRA CAPITAL MANAGEMENT, L.P.+$0.03BJANUS HENDERSON GROUP PLC+$0.03B
Top-5 holders · 49.7%
MPM BioImpact LLC--
EcoR1 Capital, LLC--
Blue Owl Capital Holdings LP--
WELLINGTON MANAGEMENT GROUP LLP--
T. Rowe Price Investment Management, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Not enough holder history to plot.
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$30.004460.0%
Last Year (2 analysts)$30.504710.0%
Current Price$20.74
Analyst Ratings
4
3
Buy: 4Hold: 3Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
16.5%retail-0.1pp
32.1%dark-2.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.